Showing 4471-4480 of 6411 results for "".
- GLP-1 Users Drive Growth in Aesthetic Surgeryhttps://practicaldermatology.com/news/glp-1-users-drive-growth-in-aesthetic-surgery/2476140/Aesthetic surgery among patients with previous glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is increasing compared with postbariatric surgery patients, according to new research published in
- Switching Biologics for Psoriasis May Improve Outcomes Without Added Risk: Studyhttps://practicaldermatology.com/news/switching-biologics-for-psoriasis-may-improve-outcomes-without-added-risk-study/2476064/Plaque psoriasis patients who are unresponsive to initial biologics may derive benefit from switching to another drug class, according to a new meta-analysis of 24 randomized controlled trials (RCTs). The review looked at da
- Study: Many May Avoid Cancer Treatment Due to Skin Side Effectshttps://practicaldermatology.com/news/study-one-third-may-avoid-cancer-treatment-due-to-skin-side-effects/2476010/A new pilot survey revealed that dermatologic side effects (DSEs) from anti-cancer therapies (ACTs) are widely misunderstood and could influence treatment decisions among patients in underserved communities. Researchers from th
- Deucravacitinib Plus Topical C/BD Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/deucravacitinib-plus-topical-cbd-effective-in-moderate-to-severe-psoriasis-analysis/2476009/New research in the Journal of Drugs in Dermatology suggests that adding topical calcipotriene/betamethasone dipropionate (C/BD) foam to oral deucravacitinib therapy improves outcomes and quality of life in patients with moderate to severe chronic plaque p
- Data Show HS Tied to Elevated Depression, Anxiety Riskhttps://practicaldermatology.com/news/data-show-hs-tied-to-elevated-depression-anxiety-risk/2475943/Patients with hidradenitis suppurativa (HS) face elevated risk of developing new-onset depression and anxiety compared with the general population, according to findings from a population-based cohort. The analysis included 1
- 2025 ASDS Survey: 70% of Consumers Considering Cosmetic Procedureshttps://practicaldermatology.com/news/2025-asds-survey-70-of-consumers-considering-cosmetic-procedures/2475889/Seventy percent of Americans are considering a cosmetic dermatologic procedure, trusting board-certified dermatologists as top influencers in patient decision-making, according to the 2025 Consumer Survey on Cosmetic Dermatologic Procedures by the American Society
- ADmirable Trial: Lebrikizumab Shows Efficacy in AD Among Skin of Color Populationshttps://practicaldermatology.com/news/admirable-lebrikizumab-shows-efficacy-in-ad-among-skin-of-color-populations/2475811/Lebrikizumab significantly improved atopic dermatitis (AD) outcomes in patients with skin of color in the ADmirable phase 3b trial. The ADmirable study, and open-label, 24-week trial evaluating lebrikizumab in patients with F
- Analysis: New Biologics Account for 70% of Increased Medicare Dermatology Drug Spendinghttps://practicaldermatology.com/news/analysis-new-biologics-account-for-70-of-increased-medicare-dermatology-drug-spending/2475722/Spending on dermatology-related drugs under Medicare Part D nearly quadrupled between 2013 and 2022, with specialty medications (including biologics) responsible for the vast majority of that increase, according to a new study.
- Anaysis: Linperlisib and Chidamide Safe, Effective in Advanced CTCLhttps://practicaldermatology.com/news/anaysis-linperlisib-and-chidamide-safe-effective-in-advanced-ctcl/2475518/An investigational combination of linperlisib and chidamide demonstrated clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), according to results from a phase 1 trial. The single-arm, n
- Study: Iron Oxide Formulation Improved Radiance in Melasma-Prone Skinhttps://practicaldermatology.com/news/study-feo-formulation-improves-radiance-in-melasma-prone-skin/2475517/A new study published in Journal of Drugs in Dermatology evaluated the incorporation of iron oxide (FeO) into a daily sun care routine could offer protection and any benefit for patients with melasma and photodamage.